Carboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small Cell Lung Cancer
Status:
Terminated
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to establish the phase II recommended dose of
Vorinostat when administered in combination with the regimen of carboplatin, paclitaxel and
bevacizumab for patients with previously untreated advanced non-small cell lunc cancer.